Oslo

• Efficacy Study of Nivolumab Compared to Placebo in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIB/C Melanoma (Ch … Ended recruitment
  2022-502354-14-00 5 2019-10-28 Completely resected Stage IIb/c melanoma
• A trial to learn if different cancer treatment combinations are safe and work in people with advanced non-small cell lung cancer that has mu … Ended recruitment
  2023-504624-25-00 4 2019-09-26 Advanced Non-Small Cell Lung Cancer
• Imaging Perfusion Restrictions from Extracellular Solid Stress - An open-label losartan study Ended recruitment
  2023-507575-22-00 4 2019-09-25 Glioblastoma - newly diagnosed and recurrent tumors (Study A)
• A Phase 3 Study to compare how effective and safe DCC-2618 is versus sunitinib in patients with GIST who have been treated previously with i … Ended recruitment
  2024-513277-52-00 5 2019-05-20 Patients with Advanced Gastrointestinal Stromal Tumors
• Study of efficacy and safety of tisagenlecleucel in HR B-ALL EOC MRD positive patients Ended recruitment
  2023-508081-15-00 4 2019-04-04 High-risk B-cell acute lymphoblastic leukemia
• Treatment for previously untreated patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with an IDH1 or IDH2 mutatio … Ended recruitment
  2022-502832-37-00 5 2019-03-01 Acute myeloid leukemia
• A Study of Avapritinib in Patients with Indolent and Systemic Mastocytosis Ended recruitment
  2024-512585-34-00 4 2019-02-27 Indolent Systemic Mastocytosis (ISM)
• Evaluation of Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Patients with Moderate to Severe Atopic Derma … Ended recruitment
  2022-502937-24-00 5 2019-01-02 Atopic Dermatitis
• A Study of combination of Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) compared to VELCADE, Lenalidomide, and … Ended recruitment
  2023-506125-10-00 5 2018-12-24 Multiple Myeloma
• Irinotecan-based triplet (FOLFOXIRI) as perioperative treatment in resectable gastric and gastroesophageal junction adenocarcinoma - a phase … Ended recruitment
  2023-509044-96-00 4 2018-12-21 Resectabel gastric and gastroesophageal junction adenocarcinoma
• The FIRST (First-line ovarian cancer treatment with Niraparib plus TSR-042) Study Ended recruitment
  2024-510605-28-00 5 2018-11-27 Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer
• A STUDY OF EFFICACY AND SAFETY OF LONG-ACTING LOW DOSE ROPEGINTERFERON IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH BOSUTINIB FROM … Ended recruitment
  2024-517417-32-00 4 2018-11-22 CHRONIC MYELOID LEUKEMIA
• Treatment with carfilzomib, lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with high-risk smoldering Multi … Ended recruitment
  2024-511334-12-00 4 2018-11-19 Smoldering Multiple Myeloma
• A randomized phase II study comparing atezolizumab after concurrent chemoradiotherapy with chemoradiotherapy alone in limited disease small- … Ended recruitment
  2024-515755-37-00 4 2018-07-31 Limited disease small-cell lung cancer
• Dual antiplatelet therapy with ticagrelor and acetylsalicylic acid (ASA) vs. ASA only after isolated coronary artery bypass grafting in pati … Ended recruitment
  2023-508551-40-00 6 2018-06-08 Coronary artery multi-vessel disease and left main stenosis
• A Study of Relatlimab plus Nivolumab Versus Nivolumab Alone in Participants with Advanced Melanoma Ended recruitment
  2024-510913-13-00 10 2018-05-18 Previously Untreated Metastatic or Unresectable Melanoma
• ENRICH - Randomised, open label study of Rituximab/Ibrutinib vs Rituximab/Chemotherapy in older patients with untreated mantle cell lymphoma Ended recruitment
  2024-514275-18-00 10 2017-12-06 Mantle Cell Lymphoma (MCL)
• B-NHL 2013 - Treatment protocol of the NHL-BFM and the NOPHO study groups for mature aggressive B-cell lymphoma and leukemia in children and … Ended recruitment
  2023-505509-18-00 5 2017-07-12 mature aggressive B-cell lymphoma and leukemia in children and adolesc
• DAHANCA 30: A randomized non-inferiority trial of hypoxia-profile guided hypoxic modification with nimorazole during radiotherapy/chemoradio … Ended recruitment
  2024-516178-31-00 5 2016-08-24 Head and neck squamous cell carcinoma (HNSCC)
• A prospective phase II study to assess the minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for … Ended recruitment
  2024-517321-99-00 4 2016-08-01 Myeloma multiplex
• PhII Trial of Pembrolizumab in Advanced Solid Tumors Ended recruitment
  2022-501253-37-00 4 2016-02-02 (A) Anal Squamous Cell Carcinoma, (B) Biliary Adenocarcinoma (gallblad
• Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage … Ended recruitment
  2023-509136-25-00 5 2015-07-16 Stage III melanoma (AJCC R0) with histologically confirmed cutaneous m
• Further 2 years of adjuvant imatinib may improve recurrence-free survival (RFS) of patients who are at a high risk of GIST recurrence despit … Ended recruitment
  2024-512243-23-00 5 2014-11-07 gastrointestinal stromal tumor
• ​​A scientific study on a vaccine against HPV infection (human papilloma virus) ​(a vaccine for the prevention of cervical cancer and genit … Ended recruitment
  2023-508683-30-00 5 2008-03-14 ​9vHPV vaccine is indicated in females ≥ 9 years of age in the prevent

Showing 385–408 of 508 trials